A939572 _SCD1 抑制剂 - MedChemExpress_第1页
A939572 _SCD1 抑制剂 - MedChemExpress_第2页
A939572 _SCD1 抑制剂 - MedChemExpress_第3页
A939572 _SCD1 抑制剂 - MedChemExpress_第4页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEA939572Cat. No.: HY-50709CAS No.: 1032229-33-6分式: CHClNO分量: 387.86作靶点: Stearoyl-CoA Desaturase (SCD)作通路: Metabolic Enzyme/Protease储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 56 mg/mL (1

2、44.38 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.5782 mL 12.8912 mL 25.7825 mL5 mM 0.5156 mL 2.5782 mL 5.1565 mL10 mM 0.2578 mL 1.2891 mL 2.5782 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 A939572种服有效的硬脂酰 CoA 去饱和酶 1 SCD1 抑

3、制剂,作于 mSCD1 和 hSCD1,IC50 分别为 4nM 和 37 nM。IC50 & Target IC50: 1体外研究A939572 exhibits robust in vivo activity with dose-dependent desaturation index lowering effects 1.A9395721/3 Master of Small Molecules 您边的抑制剂师www.MedChemEis a small molecule that specifically inhibits SCD1 enzymatic activity. A939572

4、 demonstrates a significantdose-dependent decrease in proliferation in Caki1, A498, Caki2, and ACHN at day 5 (IC50s of 65 nM, 50 nM,65 nM, and 6 nM, respectively). In A939572 (SCDi) treated Caki1 and A498 cells, all five ER stress relatedgenes are expressed at significantly increased levels compared

5、 to DMSO+BSA control, and this elevatedexpression can be blocked with the addition of OA-BSA 2.体内研究 Athymic nude (nu/nu) mice bearing A498 ccRCC xenografts are treated with A939572 (30mg/kg, p.o.) andTem individually or in combination over the course of four weeks, and tumor volume (mm3) is recorded

6、.A939572 and Tem monotherapy generate similar growth responses with approximately 20-30% reductions intumor volume (vs. placebo control) being observed upon study completion, with values reaching statisticalsignificance only within the last week of treatment. The combination group yields over a 60%

7、decrease intumor volume (vs. placebo control) by study completion with significant reductions recorded afterapproximately 1 week of treatment 2.PROTOCOLCell Assay 2 Cells are plated (0.5 or 1105/well) in 24-well plates in triplicate. Cells are counted using a Coulter ParticleCounter. Oleic acid-albu

8、min is added to media at 5Mol. A939572 stocks are prepared in DMSO.Temsirolimus dosing is performed. Soft agar cultures are prepared by diluting 2 growth medium 1:1 in 1.5%SeaplaqueGTG agarose, with 500 cells/plate in 60mm culture dishes. Colonies are stained with Giemsaand counted after 3wks 2.MCE

9、has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 2Administration 2 A498 cells are subcutaneously implanted in athymic nu/nu mice at 1106 cells/mouse in 50% Matrigel.Tumors reach 50 mm3 prior to 4 wk treatment. A939572 is re-suspended in strawberr

10、y flavored Kool-Aidin sterilized H2O (0.2 g/mL) vehicle at 30 mg/kg in a 50 L dose. Mice are orally fed by using a syringe toadminister the 50 L dose twice daily/mouse. This modified method is found to be effective and less stressfulon the mice. Temsirolimus is solubilized in 30% ethanol/saline and

11、administered via intraperitoneal injectionat 10 mg/kg in a 50 L dose once every 72 hrs/mouse. Tumor volumes are calculated using the formula0.5236 (L*W*H) and body weight are measured every 3 days.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的

12、科研献 Oncogene. 2016 Jan 28;35(4):427-37. PLoS Pathog. 2018 Aug 17;14(8):e1007261. Stem Cells. 2018 Oct;36(10):1603-1616. J Cell Mol Med. 2019 Mar;23(3):2064-2076. Front Pharmacol. 2018 Jan 4;8:960.See more customer validations on HYPERLINK / www.MedChemE2/3 Master of Small Molecules 您边的抑制剂师www.MedChe

13、mEREFERENCES1. Xin Z, et al. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. Bioorg Med Chem Lett. 2008 Aug1;18(15):4298-302.2. von Roemeling CA, et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. ClinCancer Res. 2013 May 1;19(9):2368-80.McePdf

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论